Industry Research Reports

Home > Reports > Service & Software > Global Microphysiological System Market Outlook, In‑Depth Analysis & Forecast to 2032

Global Microphysiological System Market Outlook, In‑Depth Analysis & Forecast to 2032

Industry: Service & Software

Published Date: 2026-08-15

Pages: 183 Pages

Report ld: 6991676

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Industry Insights:

Microphysiological System Research:CAGR of 19.6% during the forecast period

Microphysiological System Market Size(US$)

CAGR 2026-2032

16.2%

Market Size,2032

USD 719

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 292 million

Market Forecast in 2032(Value)

US$ 719 million

CAGR

16.2%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global Microphysiological System market is projected to grow from US$ 250 million in 2025 to US$ 719 million by 2032, at a CAGR of 16.2% (2026-2032), driven by critical product segments and diverse end‑use applications.

Microphysiological Systems (MPS) are advanced in vitro models that use human-derived cells, tissues, or organoids together with technologies such as three-dimensional culture, microfluidics, extracellular matrices, dynamic perfusion, mechanical stimulation, and integrated sensing to reproduce key structural, functional, and physiological characteristics of human tissues or organs. MPS include Organ-on-Chip systems, multi-organ platforms, organoid-based MPS, and certain engineered 3D tissue models. These systems can simulate cell-cell interactions, tissue barriers, fluid shear stress, and inter-organ communication. They are mainly used for drug screening, ADME/DMPK studies, toxicology assessment, disease modeling, precision medicine, and the reduction or replacement of animal testing, with the goal of improving the human relevance and predictive value of preclinical research.Microphysiological Systems (MPS) vary significantly in price depending on platform format, cell source, tissue model complexity, throughput, and the level of integration with perfusion, imaging, and automation. In 2025–2026, basic MPS chips or 3D culture consumables are generally priced at around US$50–1,000 per chip or plate, while complex human cell-based or organoid model kits typically range from US$500–5,000 per kit. Platforms equipped with pumping, perfusion, or culture-control functions generally cost about US$5,000–30,000 per system, while high-throughput automated MPS workstations may reach US$50,000–150,000 or more per system.

The upstream value chain mainly includes human primary cells, induced pluripotent stem cells, organoids, culture media, extracellular matrices, hydrogels, PDMS, COC/COP, glass, porous membranes, sensors, and microfluidic components. Midstream companies develop and integrate MPS chips, 3D tissue models, perfusion-control devices, and automated platforms. Downstream users mainly include pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, and regulatory agencies. MPS platforms are primarily used for drug screening, ADME/DMPK studies, toxicology assessment, disease modeling, precision medicine, and the reduction or replacement of animal testing.

Market Drivers

Growing Regulatory Support for Non-Animal Testing Methods

Regulatory agencies are increasingly encouraging the use of New Approach Methodologies, including microphysiological systems, organ-on-chip platforms, organoids, and computational models. In April 2025, the FDA released a roadmap to reduce reliance on animal testing in preclinical safety studies and specifically highlighted human-based models such as organ-on-chip systems. This regulatory shift is strengthening demand for validated MPS platforms in pharmaceutical safety and efficacy assessment.

Increasing Demand for Human-Relevant Preclinical Models

Traditional 2D cell cultures often fail to reproduce complex tissue architecture and physiological functions, while animal models may show species-specific differences in metabolism, immune response, and drug toxicity. MPS platforms recreate important biochemical, mechanical, and physiological conditions using human-derived cells and tissues, improving their potential to predict human drug responses and supporting broader adoption in drug discovery and development.

Rising Pharmaceutical R&D Efficiency Requirements

Pharmaceutical and biotechnology companies are seeking technologies that can identify ineffective or toxic candidates earlier in development. MPS platforms can support drug screening, ADME/DMPK studies, toxicity testing, disease modeling, and efficacy assessment using physiologically relevant human models. NIH continues to support tissue-chip programs designed to improve predictions of drug safety and toxicity in humans, strengthening the technology’s position within preclinical research workflows.

Market Restraints

High Platform and Experimental Costs

MPS experiments may require specialized chips or culture plates, human primary or stem-cell-derived cells, extracellular matrices, sensors, perfusion equipment, imaging systems, and dedicated analytical workflows. These requirements make MPS studies more expensive and operationally demanding than conventional 2D cell culture, particularly for small biotechnology companies and academic laboratories with limited budgets.

Insufficient Standardization and Reproducibility

Commercial MPS platforms differ substantially in materials, channel architecture, cell sources, extracellular matrices, flow conditions, assay endpoints, and operating protocols. This heterogeneity can create challenges in comparing results between laboratories and platforms. Wider regulatory and pharmaceutical adoption therefore requires improved quality control, reproducibility, standardized reporting, and fit-for-purpose validation criteria. OECD guidance increasingly emphasizes quality-management and fit-for-purpose considerations for MPS-related regulatory data.

Dependence on High-Quality Human Cells and Biological Materials

MPS performance is highly dependent on primary human cells, induced pluripotent stem-cell-derived cells, organoids, culture media, and extracellular matrices. Variability between donors and production batches, limited availability of certain mature cell types, and difficulties maintaining stable phenotypes during long-term culture can reduce reproducibility and complicate large-scale deployment. Market Opportunities

Expansion into Regulatory Toxicology and Safety Assessment

One of the largest opportunities for MPS is its transition from an academic research tool to a qualified platform for regulatory and industrial safety assessment. Liver, cardiac, kidney, lung, immune, and barrier models have particular potential for evaluating organ-specific toxicity. FDA and NIH collaboration on New Approach Methodologies is creating a more favorable environment for validated human-based models to enter formal drug-development workflows.

Development of High-Throughput and Automated MPS Platforms

Integration with multi-well formats, automated liquid handling, high-content imaging, biosensors, and data-analysis software can substantially increase MPS throughput and reproducibility. The industry is moving beyond manually operated individual chips toward scalable platforms capable of running dozens or hundreds of tissue models simultaneously, making MPS more compatible with pharmaceutical screening workflows and increasing recurring demand for consumables.

Integration with Organoids, iPSC Technology and AI

Combining MPS with patient-derived organoids, induced pluripotent stem cells, gene editing, and artificial intelligence can enable more disease-specific and patient-specific models. Such platforms could support precision medicine, patient stratification, rare-disease research, and prediction of individual drug responses. Multi-organ MPS further creates opportunities for studying systemic pharmacology, PK/PD relationships, metabolism, and organ-to-organ interactions.

Market Challenges

Balancing Physiological Complexity with Throughput and Scalability

Increasing biological realism often requires multiple cell types, vascular interfaces, extracellular matrices, mechanical stimulation, dynamic perfusion, and real-time sensing. However, greater complexity usually increases operating difficulty, cost, variability, and assay duration. Achieving sufficient physiological relevance while maintaining reproducibility, throughput, automation, and commercial scalability remains a fundamental technical challenge.

Extensive Validation Required for Regulatory Acceptance

Regulatory interest in MPS is increasing, but formal use in decision-making requires robust evidence demonstrating reproducibility, reliability, defined applicability domains, and correlation with human clinical outcomes. Cross-laboratory studies, reference-compound testing, standardized protocols, and comparison against existing methods remain necessary before individual MPS models can achieve broad regulatory acceptance.

Fragmentation of Technologies and Commercial Platforms

The MPS market includes organ-on-chip systems, organoid-based models, engineered 3D tissues, membrane and membrane-free platforms, passive and pump-driven systems, and single- and multi-organ configurations. No single architecture has emerged as the universal industry standard. This fragmentation increases platform-selection risks for pharmaceutical companies and creates significant R&D and commercialization challenges for MPS suppliers.

MARKET SEGMENTATION

By Company

Emulate
MIMETAS
TissUse
CN Bio Innovations
AIM Biotech
AlveoliX
Beonchip
React4life
InSphero
NETRI
SynVivo
BiomimX
Dynamic42
Kirkstall
Cherry Biotech
Micronit
Cellbox Labs
REVIVO BioSystems
MesoBioTech
Beijing Daxiang Biotech
AVATARGET
Suzhou Jiyan Biopharmaceutical
Altis Biosystems
28bio
Bi/ond
Ananda Devices

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Liver MPS
Lung MPS
Cardiac MPS
Kidney MPS
Gastrointestinal MPS
Neural/Brain MPS
Other

Segment by Application

Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Others

Segment by Category

Single-organ MPS
Multi-organ MPS

Segment by Division

Organ-on-Chip Systems
Organoid-based MPS
3D Engineered Tissue MPS
Others

biaoTi REPORT SCOPE

This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Microphysiological System market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by End User, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

biaoTi CHAPTER OUTLINE

Chapter 1: Defines the Microphysiological System study scope, segments the market by Type and by End User, etc, highlights segment size and growth potential

Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts

Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves

Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks

Chapter 5: Targets downstream market opportunities: evaluates market size by End User, identifies emerging use cases, and profiles leading customers by region and by End User

Chapter 6: North America: breaks down market size by End User and country, profiles key players and assesses growth drivers and barriers

Chapter 7: Europe: analyses regional market by End User and players, flagging drivers and barriers

Chapter 8: Asia Pacific: quantifies market size by End User, and region/country, profiles top players, and uncovers high potential expansion areas

Chapter 9: Central & South America: measures market size by End User, and country, profiles top players, and identifies investment opportunities and challenges

Chapter 10: Middle East and Africa: evaluates market size by End User, and country, profiles key players, and outlines investment prospects and market hurdles

Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by End User, by region SWOT analysis, and recent strategic developments

Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels

Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies

Chapter 14: Actionable conclusions and strategic recommendations.

WHY THIS REPORT

Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:

Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Study Coverage

1.1 Introduction to Microphysiological System: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Microphysiological System Market Size by Type, 2021 vs 2025 vs 2032

1.2.2 Liver MPS

1.2.3 Lung MPS

1.2.4 Cardiac MPS

1.2.5 Kidney MPS

1.2.6 Gastrointestinal MPS

1.2.7 Neural/Brain MPS

1.2.8 Other

1.3 Market Segmentation by System Integration

1.3.1 Global Microphysiological System Market Size by System Integration, 2021 vs 2025 vs 2032

1.3.2 Single-organ MPS

1.3.3 Multi-organ MPS

1.4 Market Segmentation by Platform Type

1.4.1 Global Microphysiological System Market Size by Platform Type, 2021 vs 2025 vs 2032

1.4.2 Organ-on-Chip Systems

1.4.3 Organoid-based MPS

1.4.4 3D Engineered Tissue MPS

1.4.5 Others

1.5 Market Segmentation by End User

1.5.1 Global Microphysiological System Market Size by End User, 2021 vs 2025 vs 2032

1.5.2 Pharmaceutical & Biotechnology Companies

1.5.3 Academic & Research Institutes

1.5.4 Others

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Executive Summary

2.1 Global Microphysiological System Revenue Estimates and Forecasts (2021-2032)

2.2 Global Microphysiological System Revenue by Region

2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032

2.2.2 Historical and Forecasted Revenue by Region (2021-2032)

2.2.3 Global Revenue-Based Market Share by Region (2021-2032)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape

3.1 Global Microphysiological System Players’ Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2021-2026)

3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Players (2021 vs 2025)

3.2 Global Microphysiological System Companies Headquarters and Service Footprint

3.3 Key Player Market Share by Product Type

3.3.1 Liver MPS: Market Share by Key Players

3.3.2 Lung MPS: Market Share by Key Players

3.3.3 Cardiac MPS: Market Share by Key Players

3.3.4 Kidney MPS: Market Share by Key Players

3.3.5 Gastrointestinal MPS: Market Share by Key Players

3.3.6 Neural/Brain MPS: Market Share by Key Players

3.3.7 Other: Market Share by Key Players

3.4 Global Microphysiological System Market Concentration and Dynamics

3.4.1 Global Market Concentration

3.4.2 Market Entry and Exit Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation

4.1 Global Microphysiological System Market by Type

4.1.1 Global Revenue by Type (2021-2032)

4.1.2 Global Revenue-Based Market Share by Type (2021-2032)

4.2 Global Microphysiological System Market by System Integration

4.2.1 Global Revenue by System Integration (2021-2032)

4.2.2 Global Revenue-Based Market Share by System Integration (2021-2032)

4.3 Global Microphysiological System Market by Platform Type

4.3.1 Global Revenue by Platform Type (2021-2032)

4.3.2 Global Revenue-Based Market Share by Platform Type (2021-2032)

4.4 Key Product Attributes and Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Downstream Applications and Customers

5.1 Global Microphysiological System Revenue by End User

5.1.1 Global Historical and Forecasted Revenue by End User (2021-2032)

5.1.2 Revenue-Based Market Share by End User (2021-2032)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by End User

6 North America

6.1 North America Market Size (2021-2032)

6.2 North America Key Players’ Revenue in 2025

6.3 North America Microphysiological System Market Size by End User (2021-2032)

6.4 North America Growth Accelerators and Market Barriers

6.5 North America Microphysiological System Market Size by Country

6.5.1 North America Revenue Trends by Country

6.5.2 US

6.5.3 Canada

6.5.4 Mexico

7 Europe

7.1 Europe Market Size (2021-2032)

7.2 Europe Key Players’ Revenue in 2025

7.3 Europe Microphysiological System Market Size by End User (2021-2032)

7.4 Europe Growth Accelerators and Market Barriers

7.5 Europe Microphysiological System Market Size by Country

7.5.1 Europe Revenue Trends by Country

7.5.2 Germany

7.5.3 France

7.5.4 U.K.

7.5.5 Italy

7.5.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2021-2032)

8.2 Asia-Pacific Key Players’ Revenue in 2025

8.3 Asia-Pacific Microphysiological System Market Size by End User (2021-2032)

8.4 Asia-Pacific Growth Accelerators and Market Barriers

8.5 Asia-Pacific Microphysiological System Market Size by Region

8.5.1 Asia-Pacific Revenue Trends by Region

8.6 China

8.7 Japan

8.8 South Korea

8.9 Australia

8.10 India

8.11 Southeast Asia

8.11.1 Indonesia

8.11.2 Vietnam

8.11.3 Malaysia

8.11.4 Philippines

8.11.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2021-2032)

9.2 Central and South America Key Players’ Revenue in 2025

9.3 Central and South America Microphysiological System Market Size by End User (2021-2032)

9.4 Central and South America Investment Opportunities and Key Challenges

9.5 Central and South America Microphysiological System Market Size by Country

9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)

9.5.2 Brazil

9.5.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2021-2032)

10.2 Middle East and Africa Key Players’ Revenue in 2025

10.3 Middle East and Africa Microphysiological System Market Size by End User (2021-2032)

10.4 Middle East and Africa Investment Opportunities and Key Challenges

10.5 Middle East and Africa Microphysiological System Market Size by Country

10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)

10.5.2 GCC Countries

10.5.3 Israel

10.5.4 Egypt

10.5.5 South Africa

11 Corporate Profile

11.1 Emulate

11.1.1 Emulate Corporation Information

11.1.2 Emulate Business Overview

11.1.3 Emulate Microphysiological System Product Features and Attributes

11.1.4 Emulate Microphysiological System Revenue and Gross Margin (2021-2026)

11.1.5 Emulate Microphysiological System Revenue by Product in 2025

11.1.6 Emulate Microphysiological System Revenue by End User in 2025

11.1.7 Emulate Microphysiological System Revenue by Geographic Area in 2025

11.1.8 Emulate Microphysiological System SWOT Analysis

11.1.9 Emulate Recent Developments

11.2 MIMETAS

11.2.1 MIMETAS Corporation Information

11.2.2 MIMETAS Business Overview

11.2.3 MIMETAS Microphysiological System Product Features and Attributes

11.2.4 MIMETAS Microphysiological System Revenue and Gross Margin (2021-2026)

11.2.5 MIMETAS Microphysiological System Revenue by Product in 2025

11.2.6 MIMETAS Microphysiological System Revenue by End User in 2025

11.2.7 MIMETAS Microphysiological System Revenue by Geographic Area in 2025

11.2.8 MIMETAS Microphysiological System SWOT Analysis

11.2.9 MIMETAS Recent Developments

11.3 TissUse

11.3.1 TissUse Corporation Information

11.3.2 TissUse Business Overview

11.3.3 TissUse Microphysiological System Product Features and Attributes

11.3.4 TissUse Microphysiological System Revenue and Gross Margin (2021-2026)

11.3.5 TissUse Microphysiological System Revenue by Product in 2025

11.3.6 TissUse Microphysiological System Revenue by End User in 2025

11.3.7 TissUse Microphysiological System Revenue by Geographic Area in 2025

11.3.8 TissUse Microphysiological System SWOT Analysis

11.3.9 TissUse Recent Developments

11.4 CN Bio Innovations

11.4.1 CN Bio Innovations Corporation Information

11.4.2 CN Bio Innovations Business Overview

11.4.3 CN Bio Innovations Microphysiological System Product Features and Attributes

11.4.4 CN Bio Innovations Microphysiological System Revenue and Gross Margin (2021-2026)

11.4.5 CN Bio Innovations Microphysiological System Revenue by Product in 2025

11.4.6 CN Bio Innovations Microphysiological System Revenue by End User in 2025

11.4.7 CN Bio Innovations Microphysiological System Revenue by Geographic Area in 2025

11.4.8 CN Bio Innovations Microphysiological System SWOT Analysis

11.4.9 CN Bio Innovations Recent Developments

11.5 AIM Biotech

11.5.1 AIM Biotech Corporation Information

11.5.2 AIM Biotech Business Overview

11.5.3 AIM Biotech Microphysiological System Product Features and Attributes

11.5.4 AIM Biotech Microphysiological System Revenue and Gross Margin (2021-2026)

11.5.5 AIM Biotech Microphysiological System Revenue by Product in 2025

11.5.6 AIM Biotech Microphysiological System Revenue by End User in 2025

11.5.7 AIM Biotech Microphysiological System Revenue by Geographic Area in 2025

11.5.8 AIM Biotech Microphysiological System SWOT Analysis

11.5.9 AIM Biotech Recent Developments

11.6 AlveoliX

11.6.1 AlveoliX Corporation Information

11.6.2 AlveoliX Business Overview

11.6.3 AlveoliX Microphysiological System Product Features and Attributes

11.6.4 AlveoliX Microphysiological System Revenue and Gross Margin (2021-2026)

11.6.5 AlveoliX Recent Developments

11.7 Beonchip

11.7.1 Beonchip Corporation Information

11.7.2 Beonchip Business Overview

11.7.3 Beonchip Microphysiological System Product Features and Attributes

11.7.4 Beonchip Microphysiological System Revenue and Gross Margin (2021-2026)

11.7.5 Beonchip Recent Developments

11.8 React4life

11.8.1 React4life Corporation Information

11.8.2 React4life Business Overview

11.8.3 React4life Microphysiological System Product Features and Attributes

11.8.4 React4life Microphysiological System Revenue and Gross Margin (2021-2026)

11.8.5 React4life Recent Developments

11.9 InSphero

11.9.1 InSphero Corporation Information

11.9.2 InSphero Business Overview

11.9.3 InSphero Microphysiological System Product Features and Attributes

11.9.4 InSphero Microphysiological System Revenue and Gross Margin (2021-2026)

11.9.5 InSphero Recent Developments

11.10 NETRI

11.10.1 NETRI Corporation Information

11.10.2 NETRI Business Overview

11.10.3 NETRI Microphysiological System Product Features and Attributes

11.10.4 NETRI Microphysiological System Revenue and Gross Margin (2021-2026)

11.10.5 Company Ten Recent Developments

11.11 SynVivo

11.11.1 SynVivo Corporation Information

11.11.2 SynVivo Business Overview

11.11.3 SynVivo Microphysiological System Product Features and Attributes

11.11.4 SynVivo Microphysiological System Revenue and Gross Margin (2021-2026)

11.11.5 SynVivo Recent Developments

11.12 BiomimX

11.12.1 BiomimX Corporation Information

11.12.2 BiomimX Business Overview

11.12.3 BiomimX Microphysiological System Product Features and Attributes

11.12.4 BiomimX Microphysiological System Revenue and Gross Margin (2021-2026)

11.12.5 BiomimX Recent Developments

11.13 Dynamic42

11.13.1 Dynamic42 Corporation Information

11.13.2 Dynamic42 Business Overview

11.13.3 Dynamic42 Microphysiological System Product Features and Attributes

11.13.4 Dynamic42 Microphysiological System Revenue and Gross Margin (2021-2026)

11.13.5 Dynamic42 Recent Developments

11.14 Kirkstall

11.14.1 Kirkstall Corporation Information

11.14.2 Kirkstall Business Overview

11.14.3 Kirkstall Microphysiological System Product Features and Attributes

11.14.4 Kirkstall Microphysiological System Revenue and Gross Margin (2021-2026)

11.14.5 Kirkstall Recent Developments

11.15 Cherry Biotech

11.15.1 Cherry Biotech Corporation Information

11.15.2 Cherry Biotech Business Overview

11.15.3 Cherry Biotech Microphysiological System Product Features and Attributes

11.15.4 Cherry Biotech Microphysiological System Revenue and Gross Margin (2021-2026)

11.15.5 Cherry Biotech Recent Developments

11.16 Micronit

11.16.1 Micronit Corporation Information

11.16.2 Micronit Business Overview

11.16.3 Micronit Microphysiological System Product Features and Attributes

11.16.4 Micronit Microphysiological System Revenue and Gross Margin (2021-2026)

11.16.5 Micronit Recent Developments

11.17 Cellbox Labs

11.17.1 Cellbox Labs Corporation Information

11.17.2 Cellbox Labs Business Overview

11.17.3 Cellbox Labs Microphysiological System Product Features and Attributes

11.17.4 Cellbox Labs Microphysiological System Revenue and Gross Margin (2021-2026)

11.17.5 Cellbox Labs Recent Developments

11.18 REVIVO BioSystems

11.18.1 REVIVO BioSystems Corporation Information

11.18.2 REVIVO BioSystems Business Overview

11.18.3 REVIVO BioSystems Microphysiological System Product Features and Attributes

11.18.4 REVIVO BioSystems Microphysiological System Revenue and Gross Margin (2021-2026)

11.18.5 REVIVO BioSystems Recent Developments

11.19 MesoBioTech

11.19.1 MesoBioTech Corporation Information

11.19.2 MesoBioTech Business Overview

11.19.3 MesoBioTech Microphysiological System Product Features and Attributes

11.19.4 MesoBioTech Microphysiological System Revenue and Gross Margin (2021-2026)

11.19.5 MesoBioTech Recent Developments

11.20 Beijing Daxiang Biotech

11.20.1 Beijing Daxiang Biotech Corporation Information

11.20.2 Beijing Daxiang Biotech Business Overview

11.20.3 Beijing Daxiang Biotech Microphysiological System Product Features and Attributes

11.20.4 Beijing Daxiang Biotech Microphysiological System Revenue and Gross Margin (2021-2026)

11.20.5 Beijing Daxiang Biotech Recent Developments

11.21 AVATARGET

11.21.1 AVATARGET Corporation Information

11.21.2 AVATARGET Business Overview

11.21.3 AVATARGET Microphysiological System Product Features and Attributes

11.21.4 AVATARGET Microphysiological System Revenue and Gross Margin (2021-2026)

11.21.5 AVATARGET Recent Developments

11.22 Suzhou Jiyan Biopharmaceutical

11.22.1 Suzhou Jiyan Biopharmaceutical Corporation Information

11.22.2 Suzhou Jiyan Biopharmaceutical Business Overview

11.22.3 Suzhou Jiyan Biopharmaceutical Microphysiological System Product Features and Attributes

11.22.4 Suzhou Jiyan Biopharmaceutical Microphysiological System Revenue and Gross Margin (2021-2026)

11.22.5 Suzhou Jiyan Biopharmaceutical Recent Developments

11.23 Altis Biosystems

11.23.1 Altis Biosystems Corporation Information

11.23.2 Altis Biosystems Business Overview

11.23.3 Altis Biosystems Microphysiological System Product Features and Attributes

11.23.4 Altis Biosystems Microphysiological System Revenue and Gross Margin (2021-2026)

11.23.5 Altis Biosystems Recent Developments

11.24 28bio

11.24.1 28bio Corporation Information

11.24.2 28bio Business Overview

11.24.3 28bio Microphysiological System Product Features and Attributes

11.24.4 28bio Microphysiological System Revenue and Gross Margin (2021-2026)

11.24.5 28bio Recent Developments

11.25 Bi/ond

11.25.1 Bi/ond Corporation Information

11.25.2 Bi/ond Business Overview

11.25.3 Bi/ond Microphysiological System Product Features and Attributes

11.25.4 Bi/ond Microphysiological System Revenue and Gross Margin (2021-2026)

11.25.5 Bi/ond Recent Developments

11.26 Ananda Devices

11.26.1 Ananda Devices Corporation Information

11.26.2 Ananda Devices Business Overview

11.26.3 Ananda Devices Microphysiological System Product Features and Attributes

11.26.4 Ananda Devices Microphysiological System Revenue and Gross Margin (2021-2026)

11.26.5 Ananda Devices Recent Developments

12 Microphysiological System Value Chain and Ecosystem Analysis

12.1 Microphysiological System Value Chain (Ecosystem Structure)

12.2 Upstream Analysis

12.2.1 Key Technologies, Platforms and Infrastructure

12.3 Midstream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Microphysiological System Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Microphysiological System Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

TABLE OF FIGURES

List of Tables

Table 1. Global Microphysiological System Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Table 2. Global Microphysiological System Market Size Growth Rate by System Integration, 2021 vs 2025 vs 2032 (US$ Million)

Table 3. Global Microphysiological System Market Size Growth Rate by Platform Type, 2021 vs 2025 vs 2032 (US$ Million)

Table 4. Global Microphysiological System Market Size Growth Rate by End User, 2021 vs 2025 vs 2032 (US$ Million)

Table 5. Global Microphysiological System Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 6. Global Microphysiological System Revenue by Region (US$ Million), 2021-2026

Table 7. Global Microphysiological System Revenue by Region (US$ Million), 2027-2032

Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 9. Global Microphysiological System Revenue by Players (US$ Million), 2021-2026

Table 10. Global Microphysiological System Revenue-Based Market Share by Players (2021-2026)

Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)

Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Microphysiological System Revenue, 2025

Table 13. Global Microphysiological System Average Gross Margin (%) by Player (2021 vs 2025)

Table 14. Global Microphysiological System Companies Headquarters

Table 15. Global Microphysiological System Market Concentration Ratio (CR5)

Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis

Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 18. Global Microphysiological System Revenue by Type (US$ Million), 2021-2026

Table 19. Global Microphysiological System Revenue by Type (US$ Million), 2027-2032

Table 20. Global Microphysiological System Revenue by System Integration (US$ Million), 2021-2026

Table 21. Global Microphysiological System Revenue by System Integration (US$ Million), 2027-2032

Table 22. Global Microphysiological System Revenue by Platform Type (US$ Million), 2021-2026

Table 23. Global Microphysiological System Revenue by Platform Type (US$ Million), 2027-2032

Table 24. Key Product Attributes and Differentiation

Table 25. Global Microphysiological System Revenue by End User (US$ Million), 2021-2026

Table 26. Global Microphysiological System Revenue by End User (US$ Million), 2027-2032

Table 27. Microphysiological System High-Growth Sectors Demand CAGR (2026-2032)

Table 28. Top Customers by Region

Table 29. Top Customers by End User

Table 30. North America Microphysiological System Growth Accelerators and Market Barriers

Table 31. North America Microphysiological System Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 32. Europe Microphysiological System Growth Accelerators and Market Barriers

Table 33. Europe Microphysiological System Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 34. Asia-Pacific Microphysiological System Growth Accelerators and Market Barriers

Table 35. Asia-Pacific Microphysiological System Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Central and South America Microphysiological System Investment Opportunities and Key Challenges

Table 37. Central and South America Microphysiological System Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 38. Middle East and Africa Microphysiological System Investment Opportunities and Key Challenges

Table 39. Middle East and Africa Microphysiological System Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)

Table 40. Emulate Corporation Information

Table 41. Emulate Description and Major Businesses

Table 42. Emulate Product Features and Attributes

Table 43. Emulate Revenue (US$ Million) and Gross Margin (2021-2026)

Table 44. Emulate Revenue Proportion by Product in 2025

Table 45. Emulate Revenue Proportion by End User in 2025

Table 46. Emulate Revenue Proportion by Geographic Area in 2025

Table 47. Emulate Microphysiological System SWOT Analysis

Table 48. Emulate Recent Developments

Table 49. MIMETAS Corporation Information

Table 50. MIMETAS Description and Major Businesses

Table 51. MIMETAS Product Features and Attributes

Table 52. MIMETAS Revenue (US$ Million) and Gross Margin (2021-2026)

Table 53. MIMETAS Revenue Proportion by Product in 2025

Table 54. MIMETAS Revenue Proportion by End User in 2025

Table 55. MIMETAS Revenue Proportion by Geographic Area in 2025

Table 56. MIMETAS Microphysiological System SWOT Analysis

Table 57. MIMETAS Recent Developments

Table 58. TissUse Corporation Information

Table 59. TissUse Description and Major Businesses

Table 60. TissUse Product Features and Attributes

Table 61. TissUse Revenue (US$ Million) and Gross Margin (2021-2026)

Table 62. TissUse Revenue Proportion by Product in 2025

Table 63. TissUse Revenue Proportion by End User in 2025

Table 64. TissUse Revenue Proportion by Geographic Area in 2025

Table 65. TissUse Microphysiological System SWOT Analysis

Table 66. TissUse Recent Developments

Table 67. CN Bio Innovations Corporation Information

Table 68. CN Bio Innovations Description and Major Businesses

Table 69. CN Bio Innovations Product Features and Attributes

Table 70. CN Bio Innovations Revenue (US$ Million) and Gross Margin (2021-2026)

Table 71. CN Bio Innovations Revenue Proportion by Product in 2025

Table 72. CN Bio Innovations Revenue Proportion by End User in 2025

Table 73. CN Bio Innovations Revenue Proportion by Geographic Area in 2025

Table 74. CN Bio Innovations Microphysiological System SWOT Analysis

Table 75. CN Bio Innovations Recent Developments

Table 76. AIM Biotech Corporation Information

Table 77. AIM Biotech Description and Major Businesses

Table 78. AIM Biotech Product Features and Attributes

Table 79. AIM Biotech Revenue (US$ Million) and Gross Margin (2021-2026)

Table 80. AIM Biotech Revenue Proportion by Product in 2025

Table 81. AIM Biotech Revenue Proportion by End User in 2025

Table 82. AIM Biotech Revenue Proportion by Geographic Area in 2025

Table 83. AIM Biotech Microphysiological System SWOT Analysis

Table 84. AIM Biotech Recent Developments

Table 85. AlveoliX Corporation Information

Table 86. AlveoliX Description and Major Businesses

Table 87. AlveoliX Product Features and Attributes

Table 88. AlveoliX Revenue (US$ Million) and Gross Margin (2021-2026)

Table 89. AlveoliX Recent Developments

Table 90. Beonchip Corporation Information

Table 91. Beonchip Description and Major Businesses

Table 92. Beonchip Product Features and Attributes

Table 93. Beonchip Revenue (US$ Million) and Gross Margin (2021-2026)

Table 94. Beonchip Recent Developments

Table 95. React4life Corporation Information

Table 96. React4life Description and Major Businesses

Table 97. React4life Product Features and Attributes

Table 98. React4life Revenue (US$ Million) and Gross Margin (2021-2026)

Table 99. React4life Recent Developments

Table 100. InSphero Corporation Information

Table 101. InSphero Description and Major Businesses

Table 102. InSphero Product Features and Attributes

Table 103. InSphero Revenue (US$ Million) and Gross Margin (2021-2026)

Table 104. InSphero Recent Developments

Table 105. NETRI Corporation Information

Table 106. NETRI Description and Major Businesses

Table 107. NETRI Product Features and Attributes

Table 108. NETRI Revenue (US$ Million) and Gross Margin (2021-2026)

Table 109. NETRI Recent Developments

Table 110. SynVivo Corporation Information

Table 111. SynVivo Description and Major Businesses

Table 112. SynVivo Product Features and Attributes

Table 113. SynVivo Revenue (US$ Million) and Gross Margin (2021-2026)

Table 114. SynVivo Recent Developments

Table 115. BiomimX Corporation Information

Table 116. BiomimX Description and Major Businesses

Table 117. BiomimX Product Features and Attributes

Table 118. BiomimX Revenue (US$ Million) and Gross Margin (2021-2026)

Table 119. BiomimX Recent Developments

Table 120. Dynamic42 Corporation Information

Table 121. Dynamic42 Description and Major Businesses

Table 122. Dynamic42 Product Features and Attributes

Table 123. Dynamic42 Revenue (US$ Million) and Gross Margin (2021-2026)

Table 124. Dynamic42 Recent Developments

Table 125. Kirkstall Corporation Information

Table 126. Kirkstall Description and Major Businesses

Table 127. Kirkstall Product Features and Attributes

Table 128. Kirkstall Revenue (US$ Million) and Gross Margin (2021-2026)

Table 129. Kirkstall Recent Developments

Table 130. Cherry Biotech Corporation Information

Table 131. Cherry Biotech Description and Major Businesses

Table 132. Cherry Biotech Product Features and Attributes

Table 133. Cherry Biotech Revenue (US$ Million) and Gross Margin (2021-2026)

Table 134. Cherry Biotech Recent Developments

Table 135. Micronit Corporation Information

Table 136. Micronit Description and Major Businesses

Table 137. Micronit Product Features and Attributes

Table 138. Micronit Revenue (US$ Million) and Gross Margin (2021-2026)

Table 139. Micronit Recent Developments

Table 140. Cellbox Labs Corporation Information

Table 141. Cellbox Labs Description and Major Businesses

Table 142. Cellbox Labs Product Features and Attributes

Table 143. Cellbox Labs Revenue (US$ Million) and Gross Margin (2021-2026)

Table 144. Cellbox Labs Recent Developments

Table 145. REVIVO BioSystems Corporation Information

Table 146. REVIVO BioSystems Description and Major Businesses

Table 147. REVIVO BioSystems Product Features and Attributes

Table 148. REVIVO BioSystems Revenue (US$ Million) and Gross Margin (2021-2026)

Table 149. REVIVO BioSystems Recent Developments

Table 150. MesoBioTech Corporation Information

Table 151. MesoBioTech Description and Major Businesses

Table 152. MesoBioTech Product Features and Attributes

Table 153. MesoBioTech Revenue (US$ Million) and Gross Margin (2021-2026)

Table 154. MesoBioTech Recent Developments

Table 155. Beijing Daxiang Biotech Corporation Information

Table 156. Beijing Daxiang Biotech Description and Major Businesses

Table 157. Beijing Daxiang Biotech Product Features and Attributes

Table 158. Beijing Daxiang Biotech Revenue (US$ Million) and Gross Margin (2021-2026)

Table 159. Beijing Daxiang Biotech Recent Developments

Table 160. AVATARGET Corporation Information

Table 161. AVATARGET Description and Major Businesses

Table 162. AVATARGET Product Features and Attributes

Table 163. AVATARGET Revenue (US$ Million) and Gross Margin (2021-2026)

Table 164. AVATARGET Recent Developments

Table 165. Suzhou Jiyan Biopharmaceutical Corporation Information

Table 166. Suzhou Jiyan Biopharmaceutical Description and Major Businesses

Table 167. Suzhou Jiyan Biopharmaceutical Product Features and Attributes

Table 168. Suzhou Jiyan Biopharmaceutical Revenue (US$ Million) and Gross Margin (2021-2026)

Table 169. Suzhou Jiyan Biopharmaceutical Recent Developments

Table 170. Altis Biosystems Corporation Information

Table 171. Altis Biosystems Description and Major Businesses

Table 172. Altis Biosystems Product Features and Attributes

Table 173. Altis Biosystems Revenue (US$ Million) and Gross Margin (2021-2026)

Table 174. Altis Biosystems Recent Developments

Table 175. 28bio Corporation Information

Table 176. 28bio Description and Major Businesses

Table 177. 28bio Product Features and Attributes

Table 178. 28bio Revenue (US$ Million) and Gross Margin (2021-2026)

Table 179. 28bio Recent Developments

Table 180. Bi/ond Corporation Information

Table 181. Bi/ond Description and Major Businesses

Table 182. Bi/ond Product Features and Attributes

Table 183. Bi/ond Revenue (US$ Million) and Gross Margin (2021-2026)

Table 184. Bi/ond Recent Developments

Table 185. Ananda Devices Corporation Information

Table 186. Ananda Devices Description and Major Businesses

Table 187. Ananda Devices Product Features and Attributes

Table 188. Ananda Devices Revenue (US$ Million) and Gross Margin (2021-2026)

Table 189. Ananda Devices Recent Developments

Table 190. Technologies, Platforms and Infrastructure

Table 191. Distributors List

Table 192. Market Trends and Market Evolution

Table 193. Market Drivers and Opportunities

Table 194. Market Challenges, Risks, and Restraints

Table 195. Research Programs/Design for This Report

Table 196. Key Data Information from Secondary Sources

Table 197. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Microphysiological System Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)

Figure 2. Liver MPS Product Picture

Figure 3. Lung MPS Product Picture

Figure 4. Cardiac MPS Product Picture

Figure 5. Kidney MPS Product Picture

Figure 6. Gastrointestinal MPS Product Picture

Figure 7. Neural/Brain MPS Product Picture

Figure 8. Other Product Picture

Figure 9. Global Microphysiological System Market Size Growth Rate by System Integration, 2021 vs 2025 vs 2032 (US$ Million)

Figure 10. Single-organ MPS Product Picture

Figure 11. Multi-organ MPS Product Picture

Figure 12. Global Microphysiological System Market Size Growth Rate by Platform Type, 2021 vs 2025 vs 2032 (US$ Million)

Figure 13. Organ-on-Chip Systems Product Picture

Figure 14. Organoid-based MPS Product Picture

Figure 15. 3D Engineered Tissue MPS Product Picture

Figure 16. Others Product Picture

Figure 17. Global Microphysiological System Market Size Growth Rate by End User, 2021 vs 2025 vs 2032 (US$ Million)

Figure 18. Pharmaceutical & Biotechnology Companies

Figure 19. Academic & Research Institutes

Figure 20. Others

Figure 21. Microphysiological System Report Years Considered

Figure 22. Global Microphysiological System Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 23. Global Microphysiological System Revenue (US$ Million), 2021-2032

Figure 24. Global Microphysiological System Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)

Figure 25. Global Microphysiological System Revenue-Based Market Share by Region (2021-2032)

Figure 26. Global Microphysiological System Revenue-Based Market Share Ranking (2025)

Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)

Figure 28. Liver MPS Revenue-Based Market Share by Player in 2025

Figure 29. Lung MPS Revenue-Based Market Share by Player in 2025

Figure 30. Cardiac MPS Revenue-Based Market Share by Player in 2025

Figure 31. Kidney MPS Revenue-Based Market Share by Player in 2025

Figure 32. Gastrointestinal MPS Revenue-Based Market Share by Player in 2025

Figure 33. Neural/Brain MPS Revenue-Based Market Share by Player in 2025

Figure 34. Other Revenue-Based Market Share by Player in 2025

Figure 35. Global Microphysiological System Revenue-Based Market Share by Type (2021-2032)

Figure 36. Global Microphysiological System Revenue-Based Market Share by System Integration (2021-2032)

Figure 37. Global Microphysiological System Revenue-Based Market Share by Platform Type (2021-2032)

Figure 38. Global Microphysiological System Revenue-Based Market Share by End User (2021-2032)

Figure 39. North America Microphysiological System Revenue YoY (US$ Million), 2021-2032

Figure 40. North America Top 5 Players Microphysiological System Revenue (US$ Million) in 2025

Figure 41. North America Microphysiological System Revenue (US$ Million) by End User (2021-2032)

Figure 42. US Microphysiological System Revenue (US$ Million), 2021-2032

Figure 43. Canada Microphysiological System Revenue (US$ Million), 2021-2032

Figure 44. Mexico Microphysiological System Revenue (US$ Million), 2021-2032

Figure 45. Europe Microphysiological System Revenue YoY (US$ Million), 2021-2032

Figure 46. Europe Top 5 Players Microphysiological System Revenue (US$ Million) in 2025

Figure 47. Europe Microphysiological System Revenue (US$ Million) by End User (2021-2032)

Figure 48. Germany Microphysiological System Revenue (US$ Million), 2021-2032

Figure 49. France Microphysiological System Revenue (US$ Million), 2021-2032

Figure 50. U.K. Microphysiological System Revenue (US$ Million), 2021-2032

Figure 51. Italy Microphysiological System Revenue (US$ Million), 2021-2032

Figure 52. Russia Microphysiological System Revenue (US$ Million), 2021-2032

Figure 53. Asia-Pacific Microphysiological System Revenue YoY (US$ Million), 2021-2032

Figure 54. Asia-Pacific Top 8 Players Microphysiological System Revenue (US$ Million) in 2025

Figure 55. Asia-Pacific Microphysiological System Revenue (US$ Million) by End User (2021-2032)

Figure 56. Indonesia Microphysiological System Revenue (US$ Million), 2021-2032

Figure 57. Japan Microphysiological System Revenue (US$ Million), 2021-2032

Figure 58. South Korea Microphysiological System Revenue (US$ Million), 2021-2032

Figure 59. Australia Microphysiological System Revenue (US$ Million), 2021-2032

Figure 60. India Microphysiological System Revenue (US$ Million), 2021-2032

Figure 61. Indonesia Microphysiological System Revenue (US$ Million), 2021-2032

Figure 62. Vietnam Microphysiological System Revenue (US$ Million), 2021-2032

Figure 63. Malaysia Microphysiological System Revenue (US$ Million), 2021-2032

Figure 64. Philippines Microphysiological System Revenue (US$ Million), 2021-2032

Figure 65. Singapore Microphysiological System Revenue (US$ Million), 2021-2032

Figure 66. Central and South America Microphysiological System Revenue YoY (US$ Million), 2021-2032

Figure 67. Central and South America Top 5 Players Microphysiological System Revenue (US$ Million) in 2025

Figure 68. Central and South America Microphysiological System Revenue (US$ Million) by End User (2021-2032)

Figure 69. Brazil Microphysiological System Revenue (US$ Million), 2021-2032

Figure 70. Argentina Microphysiological System Revenue (US$ Million), 2021-2032

Figure 71. Middle East and Africa Microphysiological System Revenue YoY (US$ Million), 2021-2032

Figure 72. Middle East and Africa Top 5 Players Microphysiological System Revenue (US$ Million) in 2025

Figure 73. Middle East and Africa Microphysiological System Revenue (US$ Million) by End User (2021-2032)

Figure 74. GCC Countries Microphysiological System Revenue (US$ Million), 2021-2032

Figure 75. Israel Microphysiological System Revenue (US$ Million), 2021-2032

Figure 76. Egypt Microphysiological System Revenue (US$ Million), 2021-2032

Figure 77. South Africa Microphysiological System Revenue (US$ Million), 2021-2032

Figure 78. Microphysiological System Value Chain Mapping

Figure 79. Channels of Distribution (Direct Vs Distribution)

Figure 80. Bottom-up and Top-down Approaches for This Report

Figure 81. Data Triangulation

Figure 82. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which region is expected to have the highest market share? zhanKai

For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 16.2% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.

What was the global market size of Microphysiological System in 2026? shouQi

What is the annual compound growth rate of the global Microphysiological System market size from 2026 to 2032? shouQi

What was the global market size of Microphysiological System in 2032? shouQi

Which companies rank high in the global Microphysiological System market? shouQi

Related Reports

Global Microphysiological System Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Microphysiological System market size was US$ 250 million in 2025 and is forecast to reach a readjusted size of US$ 719 million by 2032 with a CAGR of 16.2% during the forecast period 2026-2032.
Published Date: 2026-08-15
Pages: 164
USD 4250.00
(Single User License)
Global Microphysiological System Market Research Report 2026
The global Microphysiological System market was valued at US$ 250 million in 2025 and is anticipated to reach US$ 719 million by 2032, at a CAGR of 16.2% from 2026 to 2032.
Published Date: 2026-08-15
Pages: 163
USD 2900.00
(Single User License)
Microphysiological System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Microphysiological System was estimated to be worth US$ 250 million in 2025 and is projected to reach US$ 719 million, growing at a CAGR of 16.2% from 2026 to 2032.
Published Date: 2026-08-15
Pages: 175
USD 3950.00
(Single User License)
Microphysiological System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Microphysiological System was estimated to be worth US$ 148 million in 2024 and is forecast to a readjusted size of US$ 1134 million by 2031 with a CAGR of 34.3% during the forecast period 2025-2031.
Published Date: 2025-10-14
Pages: 222
USD 3950.00
(Single User License)
Microphysiological System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Microphysiological System was estimated to be worth US$ 126 million in 2024 and is forecast to a readjusted size of US$ 370 million by 2031 with a CAGR of 16.2% during the forecast period 2025-2031.
Published Date: 2025-10-13
Pages: 180
USD 3950.00
(Single User License)
Global Microphysiological System Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Microphysiological System market size was US$ 126 million in 2024 and is forecast to a readjusted size of US$ 370 million by 2031 with a CAGR of 16.2% during the forecast period 2025-2031.
Published Date: 2025-10-13
Pages: 121
USD 4250.00
(Single User License)
Global Microphysiological System Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Microphysiological System market is projected to grow from US$ 126 million in 2024 to US$ 370 million by 2031, at a CAGR of 16.2% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-10-13
Pages: 177
USD 4900.00
(Single User License)
Global Microphysiological System Market Research Report 2025
The global market for Microphysiological System was valued at US$ 126 million in the year 2024 and is projected to reach a revised size of US$ 370 million by 2031, growing at a CAGR of 16.2% during the forecast period.
Published Date: 2025-10-13
Pages: 119
USD 2900.00
(Single User License)
Global and China Microphysiological System Market Report & Forecast 2024-2030
Microphysiological Systems (MPS) are in vitro models composed of cells, tissue explants, or stem-cell derived 'organoid' formations of human or animal origin. These models provide translational biochemical, electrical, and/or physiomechanical responses to represent organ and tissue function, with great potential to replace some animals used in research. According to the U.S. Food and Drug Administration (FDA), MPS model "functional features of a specific tissue or organ of human or animal origin by exposing cells to a microenvironment that mimics the physiological aspects important for their function or pathophysiological condition." These systems are being developed to better mimic some aspects of specific organ systems or combinations of organ systems to improve upon standard two-dimensional (2D) cell systems, with the goal of eventually replacing animal models being used for hazard identification, risk assessment, and disease modeling, among other uses.
Published Date: 2024-09-04
Pages: 165
USD 4350.00
(Single User License)
Microphysiological System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Microphysiological Systems (MPS) are in vitro models composed of cells, tissue explants, or stem-cell derived 'organoid' formations of human or animal origin. These models provide translational biochemical, electrical, and/or physiomechanical responses to represent organ and tissue function, with great potential to replace some animals used in research. According to the U.S. Food and Drug Administration (FDA), MPS model "functional features of a specific tissue or organ of human or animal origin by exposing cells to a microenvironment that mimics the physiological aspects important for their function or pathophysiological condition." These systems are being developed to better mimic some aspects of specific organ systems or combinations of organ systems to improve upon standard two-dimensional (2D) cell systems, with the goal of eventually replacing animal models being used for hazard identification, risk assessment, and disease modeling, among other uses.
Published Date: 2024-09-04
Pages: 168
USD 3950.00
(Single User License)

Global Microphysiological System Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Microphysiological System market size was US$ 250 million in 2025 and is forecast to reach a readjusted size of US$ 719 million by 2032 with a CAGR of 16.2% during the forecast period 2026-2032.
Published: 2026-08-15
Pages: 164
USD 4250.00 (Single User License)
Global Microphysiological System Market Research Report 2026
The global Microphysiological System market was valued at US$ 250 million in 2025 and is anticipated to reach US$ 719 million by 2032, at a CAGR of 16.2% from 2026 to 2032.
Published: 2026-08-15
Pages: 163
USD 2900.00 (Single User License)
Microphysiological System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Microphysiological System was estimated to be worth US$ 250 million in 2025 and is projected to reach US$ 719 million, growing at a CAGR of 16.2% from 2026 to 2032.
Published: 2026-08-15
Pages: 175
USD 3950.00 (Single User License)
Microphysiological System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Microphysiological System was estimated to be worth US$ 148 million in 2024 and is forecast to a readjusted size of US$ 1134 million by 2031 with a CAGR of 34.3% during the forecast period 2025-2031.
Published: 2025-10-14
Pages: 222
USD 3950.00 (Single User License)
Microphysiological System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Microphysiological System was estimated to be worth US$ 126 million in 2024 and is forecast to a readjusted size of US$ 370 million by 2031 with a CAGR of 16.2% during the forecast period 2025-2031.
Published: 2025-10-13
Pages: 180
USD 3950.00 (Single User License)
Global Microphysiological System Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Microphysiological System market size was US$ 126 million in 2024 and is forecast to a readjusted size of US$ 370 million by 2031 with a CAGR of 16.2% during the forecast period 2025-2031.
Published: 2025-10-13
Pages: 121
USD 4250.00 (Single User License)
Global Microphysiological System Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Microphysiological System market is projected to grow from US$ 126 million in 2024 to US$ 370 million by 2031, at a CAGR of 16.2% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-10-13
Pages: 177
USD 4900.00 (Single User License)
Global Microphysiological System Market Research Report 2025
The global market for Microphysiological System was valued at US$ 126 million in the year 2024 and is projected to reach a revised size of US$ 370 million by 2031, growing at a CAGR of 16.2% during the forecast period.
Published: 2025-10-13
Pages: 119
USD 2900.00 (Single User License)
Global and China Microphysiological System Market Report & Forecast 2024-2030
Microphysiological Systems (MPS) are in vitro models composed of cells, tissue explants, or stem-cell derived 'organoid' formations of human or animal origin. These models provide translational biochemical, electrical, and/or physiomechanical responses to represent organ and tissue function, with great potential to replace some animals used in research. According to the U.S. Food and Drug Administration (FDA), MPS model "functional features of a specific tissue or organ of human or animal origin by exposing cells to a microenvironment that mimics the physiological aspects important for their function or pathophysiological condition." These systems are being developed to better mimic some aspects of specific organ systems or combinations of organ systems to improve upon standard two-dimensional (2D) cell systems, with the goal of eventually replacing animal models being used for hazard identification, risk assessment, and disease modeling, among other uses.
Published: 2024-09-04
Pages: 165
USD 4350.00 (Single User License)
Microphysiological System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Microphysiological Systems (MPS) are in vitro models composed of cells, tissue explants, or stem-cell derived 'organoid' formations of human or animal origin. These models provide translational biochemical, electrical, and/or physiomechanical responses to represent organ and tissue function, with great potential to replace some animals used in research. According to the U.S. Food and Drug Administration (FDA), MPS model "functional features of a specific tissue or organ of human or animal origin by exposing cells to a microenvironment that mimics the physiological aspects important for their function or pathophysiological condition." These systems are being developed to better mimic some aspects of specific organ systems or combinations of organ systems to improve upon standard two-dimensional (2D) cell systems, with the goal of eventually replacing animal models being used for hazard identification, risk assessment, and disease modeling, among other uses.
Published: 2024-09-04
Pages: 168
USD 3950.00 (Single User License)